

FDA-Indexed vs. Compounded Pharmaceuticals

*A Critical Comparison for Zoo & Wildlife Veterinary
Professionals*

**TECHNICAL, SCIENTIFIC, COMMERCIAL & REGULATORY
ANALYSIS**

Prepared For:

Zoo Veterinarians, Wildlife Practitioners, and Exotic Animal Specialists

Prepared by Clovis Davis Pharmaceuticals | March 2026
FOR VETERINARY PROFESSIONAL USE ONLY

Table of Contents

■ SECTION 1: Executive Summary.....	3
■ SECTION 2: Regulatory & Legal Framework.....	4
■ SECTION 3: Manufacturing & Quality Assurance.....	5
■ SECTION 4: Clinical & Safety Implications.....	6
■ SECTION 5: Liability & Malpractice Risk	8
■ SECTION 6: Commercial & Practical Considerations.....	9
■ SECTION 7: The Indexed Drug Advantage for Minor Species...	10
■ SECTION 8: When is Compounding Appropriate?	11
■ SECTION 9: Decision-Making Flowchart.....	12
■ SECTION 10: Key Takeaways & Recommendations	13
■ SECTION 11: Resources & References	14


Section 1: Executive Summary

This document provides a critical analysis of the shift from compounded to FDA-indexed pharmaceuticals in zoo and wildlife medicine. As new drugs for minor species achieve FDA Indexing status, the legal and regulatory landscape for veterinary prescribing changes fundamentally. This transition offers significant benefits in quality assurance, dosing accuracy, and liability protection, but requires veterinarians to adjust procurement practices to remain compliant with federal law.

CRITICAL TAKEAWAY: Once a drug is listed on the FDA Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, compounding pharmacies are legally prohibited from compounding "essentially copies" of that drug. Continued prescribing of compounded formulations when an indexed product exists exposes veterinarians to significant legal, regulatory, and liability risks.

Quick Comparison: The Indexing Advantage

Feature	FDA-Indexed Drugs	Compounded Drugs
Legal Status	Legally marketed, federally recognized	Unapproved; restricted when indexed drug exists
Manufacturing	cGMP compliant; FDA inspected facilities	Variable (503A); rarely FDA inspected
Concentration	Guaranteed $\pm 5\%$ (USP standards)	Variable (Risk of $\pm 20\text{--}40\%$ error)
Sterility	FDA-validated sterility testing	Pharmacy-validated (risk of contamination)
Liability	Standard of care; malpractice coverage applies	High risk; may be excluded from insurance



Section 2: Regulatory & Legal Framework

What is FDA MUMS Indexing?

The Minor Use and Minor Species (MUMS) Animal Health Act of 2004 established the "Indexing" pathway to provide a legal mechanism for marketing drugs for minor species (zoo animals, wildlife, etc.) where traditional FDA approval is impractical due to small market size. A drug listed on the Index has undergone FDA review for safety (to the target animal and humans) and effectiveness for its intended use.

Reference: [FDA Drug Indexing](#)

Legal Status: Indexed vs. Compounded

Indexed drugs are legally marketed products. Compounded drugs are unapproved new animal drugs that the FDA exercises enforcement discretion over, provided specific conditions are met. One of the most critical conditions is that **compounding cannot be done to copy a commercially available FDA-approved or indexed product.**

FDA GFI #256: Restriction on Bulk Compounding

FDA Guidance for Industry (GFI) #256 clarifies that compounding from bulk drug substances is generally prohibited when an FDA-approved or indexed product can be used (on-label or extra-label). Compounding "copies" of indexed drugs for economic reasons is a direct violation of FDA policy.

AMDUCA & Extra-Label Use

Under the Animal Medicinal Drug Use Clarification Act (AMDUCA), veterinarians may use FDA-approved drugs in an extra-label manner. However, **indexed drugs cannot be used extra-label** under federal law. Conversely, using a compounded drug is legally considered extra-label use, which is only permitted when no approved or indexed drug is available to treat the condition.

CRITICAL REGULATORY POINT:

Once a drug is FDA-indexed, compounding pharmacies are **LEGALLY PROHIBITED** from compounding equivalent formulations. Veterinarians who continue to prescribe compounded copies may face board complaints, federal scrutiny, and malpractice liability for deviating from the legal standard of care.

Note on State Pharmacy Boards: While state boards regulate pharmacy practice, they generally defer to FDA determinations regarding the legality of compounding copies of commercially available drugs.

Section 3: Manufacturing & Quality Assurance

The discrepancy in quality assurance between FDA-indexed manufacturing and pharmacy compounding is substantial. Indexed drugs must meet Current Good Manufacturing Practice (cGMP) regulations, whereas traditional 503A compounding pharmacies are exempt from cGMP.

Quality Parameter	FDA-Indexed Drugs (cGMP)	Compounded Drugs (503A)
Manufacturing Standards	Must comply with 21 CFR 211 (cGMP). Rigorous process validation.	Exempt from cGMP. Follow USP <795>/<797> (procedural standards, not manufacturing).
FDA Inspections	Mandatory pre-approval inspection; routine surveillance inspections.	Rarely inspected by FDA; oversight primarily by state boards with limited resources.
Batch Testing	Every batch tested for identity, strength, quality, and purity before release.	Limited testing; often "skip-lot" or based on theoretical yield calculations.
Sterility Assurance	Validated sterilization cycles; end-product sterility testing mandatory.	Process-based; sterility testing of final product not always performed for every batch.
Concentration Accuracy	Strict adherence to USP monograph (typically $\pm 5\%$ limit).	Variable. Studies show fluctuations of $\pm 20\text{-}40\%$ are common.
Stability/Shelf-Life	determined by real-time stability studies under controlled conditions.	"Beyond-Use Date" (BUD) estimated based on literature, rarely specific stability data.
Ingredients	FDA-approved pharmaceutical grade sources only.	Bulk chemicals; quality certificates (CoA) relied upon but not always independently verified.
Adverse Events	Mandatory reporting to FDA (Pharmacovigilance).	Reporting voluntary; no central database for tracking safety issues.

Scientific Evidence of Variability

- Studies published in *JAVMA* (2017) found that compounded doxycycline formulations **lost 30-40% potency within 3 weeks** of receipt, despite labeling indicating longer shelf-life.
- A 2021 study in *Veterinary Ophthalmology* found that compounded famciclovir suspensions showed **concentration variability of 0.5% to 29%** between batches from the same pharmacy.
- Research on compounded meloxicam found that **12 of 19 formulations did not contain the labeled concentration**, posing significant risks of therapeutic failure or toxicity.

Section 4: Clinical Safety & Implications

4.1 Dosing Accuracy & Predictability

For zoo and wildlife medicine, the predictability of drug effect is paramount. Indexed drugs are manufactured to deliver a precise dose every time. Compounded drugs, due to manual preparation methods, inherently carry higher batch-to-batch variability.

Indexed Drugs: Consistent concentration leads to predictable immobilization depth and recovery times.

Compounded Drugs: Variability creates a "moving target," forcing veterinarians to guess if a lack of effect is due to physiology or low drug concentration.

CRITICAL FOR WILDLIFE IMMOBILIZATION:

In zoo and wildlife immobilization, dosing accuracy is **CRITICAL**. Overdose can cause respiratory arrest and death. Underdose can result in inadequate sedation, leading to human injury, animal escape, or animal injury from prolonged pursuit (capture myopathy). Compounded drug concentration variability introduces unacceptable risk in field immobilization scenarios.

4.2 Bioavailability & Formulation Issues

Drug delivery systems are complex. Simply mixing an active ingredient into a base does not guarantee absorption.

- **Transdermal Gels:** Compounded transdermal gels often lack specific bioavailability studies demonstrating drug penetration. Therapeutic failure due to poor absorption is a documented risk.
- **Sustained-Release:** "Slow-release" compounded formulations may dump the dose immediately or fail to release it at all, leading to erratic plasma levels.
- **Example:** Comparisons between compounded transdermal buprenorphine and FDA-approved versions (like Zorbiu) often show significantly lower and more variable plasma concentrations with the compounded product.

4.3 Sterility & Contamination Risk

Injectable drugs intended for wildlife often have high concentrations. Compounding these requires manipulating non-sterile bulk powders.

- **Microbial Contamination:** 503A pharmacies are not required to test every batch for sterility. This increases the risk of introducing bacteria or fungi into high-value animals.

- **Particulate Matter:** Compounded solutions may contain visible or sub-visible particles that can cause embolisms or inflammation.
- **Case History:** FDA warning letters to compounding pharmacies frequently cite "insufficient sterility assurance" and "contaminated sterile products" as primary violations.

Section 5: Liability & Malpractice Risk

Moving beyond clinical science, the legal implications of using compounded drugs when an indexed version is available are profound.

5.1 Veterinary Malpractice Exposure

The legal "Standard of Care" dictates using FDA-approved or indexed products when available. Deviating from this standard by prescribing a compounded "copy" without a valid medical justification (e.g., patient allergy) exposes the veterinarian to liability.

Insurance Gaps: The AVMA PLIT has issued risk alerts stating: *"Compounding pharmacy product liability insurance may exclude compounding activity. Veterinarians may become litigation targets."* If a pharmacy's insurance denies a claim, the plaintiff will almost certainly pursue the prescribing veterinarian.

REAL CASE STUDY:

In 2015, a racehorse died after administration of a compounded drug. The owners sued. The compounding pharmacy filed a **third-party complaint against the prescribing veterinarian**, making the vet a party to expensive and complex litigation. The vet had not been named in the original suit but was dragged in by the pharmacy to share liability.

5.2 DEA Controlled Substance Liability

Many wildlife immobilization drugs are Schedule III or IV controlled substances.

- **Indexed Drugs:** Have a clear, federally tracked chain of custody from manufacturer to distributor to veterinarian.
- **Compounded Drugs:** Involve transfers between registrants that can be legally complex. "Office use" compounding of controlled substances is heavily restricted and often violates the Controlled Substances Act if not strictly compliant with the specific constructive transfer rules.

5.3 State Veterinary Board Complaints

State boards define unprofessional conduct. Prescribing a compounded drug that is a copy of a commercially available indexed drug—especially if driven by cost rather than medical need—can be interpreted as unprofessional conduct, potentially threatening a veterinary license.

Section 6: Commercial & Practical Considerations

While the initial cost of compounded drugs may appear lower, the total cost of ownership—including waste, liability, and workflow efficiency—often favors indexed products.

Factor	FDA-Indexed Drugs	Compounded Drugs
Availability	Consistent supply through authorized veterinary distributors.	Variable; depends on individual pharmacy capacity and bulk powder sourcing.
Ordering Process	Standard ordering (Covetrus, MWI, etc.). Integrated into practice management software.	Requires individual pharmacy relationship, specific patient prescriptions, and separate accounts.
Shelf-Life	18-36 months typical (based on data).	30-180 days "Beyond-Use Date" (BUD).
Inventory	Easier; longer shelf-life allows stocking. Reduces expired product waste.	Difficult; short shelf-life leads to frequent re-ordering and high waste of expired product.
Cost	Transparent pricing. Higher upfront, but zero liability cost.	Variable. "Hidden costs" include liability risk, waste, and potential therapeutic failure/re-treatment.
Emergency	Stocked by distributors for next-day delivery.	Must be specially compounded; delays of 2-5 days are common.
Labeling	Complete, FDA-reviewed package insert with dosing, safety, and pharmacology data.	Limited labeling; often generic guidance without specific safety data.
Traceability	Full DSCSA supply chain documentation.	Limited; dependent on pharmacy records.

Section 7: The Indexed Drug Advantage for Minor Species

The FDA MUMS Act was specifically designed to solve the problem of drug availability for minor species. Indexing is not a loophole; it is a rigorous scientific review process tailored to species where full approval studies are impossible (e.g., you cannot run a 500-animal clinical trial on endangered tigers).

Purpose-Built for Zoo & Wildlife

Indexed drugs are not repurposed human drugs; they are developed specifically for veterinary needs.

- **CDP's Portfolio:**
 - **Sedolam 50 (midazolam) Expected April 2026**
 - **Butadyne 50 (butorphanol) Not Available/Under Review 2026**
 - **Dormadet 40 (medetomidine) Not Available/Under Review 2026**
 - **Zoosedin 20 (atipamezole) Not Available/Under Review 2027**
 - **Azaperone Not Available 2027**
 - **Ketamine Not Available 2027**

These formulations are purpose-built for high-concentration wildlife immobilization, ensuring small dart volumes with FDA-verified sterility and potency.

Section 8: When is Compounding Appropriate?

We recognize that compounding remains a vital tool in veterinary medicine. It is not about eliminating compounding, but restricting it to its legal and medical purpose: filling gaps where no approved drug exists.

Legitimate Medical Needs for Compounding

1. **No FDA-Approved/Indexed Product Exists:** If there is no drug available for the species/indication, compounding is necessary.
2. **Allergy/Toxicity:** If the approved/indexed product contains an excipient (preservative, dye, carrier) toxic or allergenic to the specific patient.
3. **Concentration Requirement:** If the patient requires a concentration that cannot be achieved by manipulating (diluting) the approved product.

Regulatory Constraints

- **Patient-Specific Use:** Allowed under AMDUCA *only* if a valid veterinarian-client-patient relationship (VCPR) exists and the clinical difference is documented.
- **Office Stock:** Generally prohibited for non-food animals unless the substance appears on the FDA's specific "List of Bulk Drug Substances for Compounding Office Stock."

KEY POINT: Compounding should **NEVER** be chosen for economic reasons when an indexed or approved product is available. This violates FDA extra-label drug use rules and exposes the veterinarian to malpractice liability.

Section 9: Decision-Making Flowchart

Use this logic tree to determine the legally compliant prescribing path for your zoo or wildlife patient.

```
START: Need to treat zoo/wildlife patient ↓ Is there an FDA-INDEXED drug for this
      Yes→ USE INDEXED DRUG (Required; compounding copies is illegal)
      ↓ NO Is there an FDA-APPROVED drug (animal or human) that can be used extra-label
      Yes→ USE APPROVED DRUG EXTRA-LABEL (Preferred Standard of Care)
      ↓ NO Can the patient's needs be met by compounding FROM an approved/indexed
      product
      Yes→ COMPOUND FROM APPROVED/INDEXED PRODUCT (Acceptable)
      ↓ NO ↓ Document clinical rationale (why approved drug fails) ↓
      → COMPOUND FROM BULK (Last resort; must meet GFI #256 requirements)
```

Section 10: Key Takeaways & Recommendations

1. **Always use FDA-indexed drugs when available** for the species/indication.
Compounding copies is illegal post-indexing.
 2. **Indexed drugs provide superior quality assurance**, batch consistency, sterility, and liability protection compared to compounded alternatives.
 3. **In zoo/wildlife immobilization, dosing accuracy is life-or-death.** Compounded drug variability introduces an unacceptable safety risk.
 4. **Veterinarians prescribing compounded copies of indexed drugs face malpractice and board complaint risk** for deviating from the standard of care.
 5. **Compounding pharmacies may not carry adequate liability insurance** for compounding activities. You may become the primary litigation target in an adverse event.
 6. **When compounding is medically necessary, document your clinical rationale thoroughly** in the medical record to justify bypassing approved products.
 7. **DEA controlled substances:** Indexed drugs provide a clear, legal chain of custody and ensure compliance with federal law.
 8. **Ask your compounding pharmacy** for proof of product liability insurance and GMP compliance if you absolutely must use compounded products for valid medical reasons.
-

Section 11: Resources & References

Regulatory Links

- **FDA Drug Indexing:** <https://www.fda.gov/animal-veterinary/minor-use/minor-species/drug-indexing>
- **FDA GFI #256 (Compounding):** [View Guidance Document](#)
- **AVMA Compounding FAQs:** [AVMA Resources](#)
- **AVMA PLIT Risk Alert:** [Liability Alerts](#)

Scientific Citations

- *Evaluation of drug content (potency) for compounded doxycycline.* JAVMA, 2017.
- *Variable accuracy of compounded famciclovir formulations.* Veterinary Ophthalmology, 2021.
- *Evaluation of the amount of compounded chemotherapy drugs.* Veterinary and Comparative Oncology, 2024.

CDP

Clovis Davis Pharmaceuticals
